Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 12/20 | 0.44 |
| ▸ | IGF1R | P08069 | 12/20 | 0.44 |
| ▸ | KDR | P35968 | 11/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 2/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852107 | 0.89 | ITK (0.45) | FGFR1IGF1RKDRITKCCNA2 | |
| SCHEMBL4011622 | 0.85 | IGF1R (0.49) | FGFR1IGF1RKDRITKINSR | |
| SCHEMBL4012227 | 0.84 | FGFR1 (0.60) | FGFR1IGF1RKDRITKINSR | |
| SCHEMBL3939428 | 0.83 | IGF1R (0.54) | FGFR1IGF1RKDRITKPAK1 | |
| SCHEMBL4011783 | 0.83 | FGFR1 (0.58) | FGFR1IGF1RKDRITKINSR | |
| SCHEMBL2120764 | 0.81 | ITK (0.62) | FGFR1IGF1RKDRITKINSR | |
| SCHEMBL4086501 | 0.81 | FGFR1 (0.65) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL3940505 | 0.81 | FGFR1 (0.55) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL4089841 | 0.80 | FGFR1 (0.54) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL27773498 | 0.80 | FGFR1 (0.46) | FGFR1IGF1RKDRITKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | FGFR1 1428/4885IGF1R 3217/4885KDR 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.